Efficacy and safety of cinacalcet for the treatment of secondary hyperparathyroidism in patients with advanced chronic kidney disease before initiation of regular dialysis

Nephrology

Volumn 17, Issue 1, 2012, Pages 26-31

  Montenegro, Jesús ^a   Cornago, Iñaki ^a   Gallardo, Isabel ^a   García Ledesma, Paula ^a   Hernando, Ainhoa ^a   Martinez, Isabel ^a   Muñoz, Rosa I ^a   Romero, Marco A ^a  

^a HOSPITAL DE GALDAKAO   (Spain)

Author keywords

calcimimetic; chronic kidney disease; cinacalcet; predialysis; secondary hyperparathyroidism

Indexed keywords

CALCITRIOL; CALCIUM; CALCIUM CARBONATE; CINACALCET; CREATININE; ERYTHROPOIETIN; LANTHANUM CARBONATE; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE BINDING AGENT; PHOSPHORUS; PROTEIN; THIAZIDE DIURETIC AGENT;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE URINE LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIURETIC THERAPY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PHOSPHATE URINE LEVEL; PRIORITY JOURNAL; PROTEIN URINE LEVEL; SECONDARY HYPERPARATHYROIDISM; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

ADULT; AGED; CALCIMIMETIC AGENTS; CALCIUM; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY DISEASES; MALE; MIDDLE AGED; NAPHTHALENES; PARATHYROID HORMONE; PHOSPHORUS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VITAMIN D;

EID: 84855163776     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2011.01530.x     Document Type: Article

References (25)

1. Martinez I, Saracho R, Montenegro J, Llach F,. The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am. J. Kidney Dis. 1997; 29: 496-502. (Pubitemid 27155269)
2. Joy MS, Karagiannis PC, Peyerl FW,. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. J. Manag. Care Pharm. 2007; 13: 397-411. (Pubitemid 47162414)
3. Rodriguez M, Lorenzo V,. Parathyroid hormone, a uremic toxin. Semin. Dial. 2009; 22: 363-8.
4. Andress DL, Coyne DW, Kalantar-Zadeh K, Molitch ME, Zangeneh F, Sprague SM,. Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Endocr. Pract. 2008; 14: 18-27.
5. Messa P, Alfieri C, Brezzi B,. Cinacalcet: Pharmacological and clinical aspects. Expert Opin. Drug Metab. Toxicol. 2008; 4: 1551-60.
6. Rodriguez M, Nemeth E, Martin D,. The calcium-sensing receptor: A key factor in the pathogenesis of secondary hyperparathyroidism. Am. J. Physiol. Renal Physiol. 2005; 288: F253-64. (Pubitemid 40105383)
7. Charytan C, Coburn JW, Chonchol M, et al,. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am. J. Kidney Dis. 2005; 46: 58-67. (Pubitemid 40852012)
8. Chonchol M, Locatelli F, Abboud HE, et al,. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am. J. Kidney Dis. 2009; 53: 197-207.
9. Coyne DW,. Cinacalcet should not be used to treat secondary hyperparathyroidism in stage 3-4 chronic kidney disease. Nat. Clin. Pract. Nephrol. 2008; 4: 364-5. (Pubitemid 351913685)
10. Cannata-Andía JB, Fernández-Martín JL,. Mineral metabolism: Should cinacalcet be used in patients who are not on dialysis? Nat. Rev. Nephrol. 2009; 5: 307-8.
11. Kalantar-Zadeh K, Kovesdy CP,. Is it worth correcting hyperparathyroidism if hyperphosphatemia and hypocalcemia worsen? A cinacalcet story. Am. J. Kidney Dis. 2009; 53: 183-8.
12. Shahapuni I, Monge M, Oprisiu R, et al,. Drug Insight: Renal indications of calcimimetics. Nat. Clin. Pract. Nephrol. 2006; 2: 316-25. (Pubitemid 44058967)
13. de Francisco AL, Piñera C, Palomar R,. Cinacalcet should be used to treat secondary hyperparathyroidism in stage 3-4 chronic kidney disease. Nat. Clin. Pract. Nephrol. 2008; 4: 366-7. (Pubitemid 351913694)
14. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D,. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann. Intern. Med. 1999; 130: 461-70. (Pubitemid 29135798)
15. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. 2003; 42 (4 Suppl 3): S1-201.
16. Bolasco P,. Treatment options of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease stages 3 and 4: An historic review. Clin. Cases Miner. Bone Metab. 2009; 6: 210-19.
17. Drüeke TB, Ritz E,. Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives. Clin. J. Am. Soc. Nephrol. 2009; 4: 234-41.
18. Block GA, Zeig S, Sugihara J, et al,. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol. Dial. Transplant. 2008; 23: 2311-18. (Pubitemid 351957604)
19. Forslund T, Koistinen A, Miettinen M,. Experience with cinacalcet for secondary hyperparathyroidism in patients with chronic kidney disease stage III and IV. Clin. Med. Ther. 2009; 1: 801-8.
20. Raggi P, Boulay A, Chasan-Taber S, et al,. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J. Am. Coll. Cardiol. 2002; 39: 695-701. (Pubitemid 34158168)
21. Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A,. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: Evidence for the complexity of the association between mineral metabolism and outcomes. J. Am. Soc. Nephrol. 2004; 15: 770-9. (Pubitemid 38294808)
22. Kestenbaum B, Sampson JN, Rudser KD, et al,. Serum phosphate levels and mortality risk among people with chronic kidney disease. J. Am. Soc. Nephrol. 2005; 16: 520-8. (Pubitemid 41725150)
23. Chonchol M, Wüthrich RP,. Potential future uses of calcimimetics in patients with chronic kidney disease. NDT Plus. 2008; 1 (Suppl 1): i36-41. (Pubitemid 351260304)
24. Jüppner H, Wolf M, Salusky IB,. FGF23: More than a regulator of renal phosphate handling? J. Bone Miner. Res. 2010; 25: 2091-7.
25. Finch JL, Tokumoto M, Nakamura H, et al,. Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease. Am. J. Physiol. Renal Physiol. 2010; 298: F1315-22.